Which selective serotonin reuptake inhibitors (SSRIs) are considered for body‑dysmorphic disorder?

Which SSRIs Are Considered for Body Dysmorphic Disorder

All SSRIs are considered for BDD, but fluoxetine has the strongest evidence from placebo-controlled trials, while citalopram and escitalopram have demonstrated efficacy in open-label studies. 1, 2

Evidence-Based SSRI Selection

First-Line SSRI Options

The NICE guidelines recommend SSRIs as second-line treatment for young people aged 12-18 years with moderate to severe BDD who have not responded adequately to CBT 1. However, the evidence base supports several specific SSRIs:

Fluoxetine is the most rigorously studied SSRI for BDD, with the only published placebo-controlled RCT demonstrating:

• 53% response rate versus 18% with placebo (p=0.003)
• Significant improvement beginning at week 8 and continuing through week 12
• Efficacy in both delusional and non-delusional BDD patients
• Protective effect against suicidality worsening compared to placebo 2, 3

Citalopram showed promising results in open-label trials:

• 73.3% response rate
• Mean dose of 51.3 mg/day
• Mean time to response of 4.6 weeks
• Significant improvements in psychosocial functioning and quality of life 4

Escitalopram demonstrated efficacy in open-label studies:

• 73.3% response rate
• 46.7% of subjects were "very much improved"
• Well-tolerated with improvements in depressive symptoms, delusionality, and functioning 5

Key Treatment Principles

High doses and extended duration are typically required 6, 7:

• SSRIs should be prescribed at higher doses than typically used for depression
• Treatment duration of at least 12 weeks is necessary to establish full benefit
• This differs from standard depression treatment protocols

Clomipramine (a non-selective SRI) has also shown efficacy superior to desipramine in reducing symptom severity 8, though SSRIs are preferred due to better tolerability.

Clinical Algorithm

1. Start with any SSRI - fluoxetine, citalopram, or escitalopram based on availability and patient factors
2. Titrate to high doses - higher than typical antidepressant dosing
3. Allow adequate trial duration - minimum 12 weeks before determining response
4. Monitor for response - expect gradual improvement starting around weeks 4-8
5. Consider augmentation strategies if inadequate response, including atypical antipsychotics or levetiracetam 6

Important Caveats

• The evidence base consists primarily of small studies with heterogeneous designs 9
• Most research has been conducted in adults, with limited data in adolescents 1
• SSRIs show large effect sizes (SMD = -1.16) comparable to CBT (SMD = -1.12) for reducing depressive symptoms in BDD 9
• Combined pharmacotherapy and CBT may provide optimal outcomes 9, 6
• Antipsychotics alone are not indicated for BDD, even with delusional beliefs 7